{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:09:01Z","timestamp":1792786141424,"version":"4.5.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","funder":[{"name":"National Research Foundation","award":["PMDS22052715222"],"award-info":[{"award-number":["PMDS22052715222"]}]},{"name":"Cancer Association of South Africa","award":["CANSA does not allocate formal grant numbers for funding awards"],"award-info":[{"award-number":["CANSA does not allocate formal grant numbers for funding awards"]}],"id":[{"id":"https:\/\/ror.org\/00ppjep56","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Breast cancer is a leading cause of cancer-related mortality in women globally. Breast cancer patients treated with tamoxifen demonstrate interpatient variability, with adherence challenges affecting up to 50% of patients by year 5, directly impacting the concentrations of the active metabolite of tamoxifen, namely endoxifen, and clinical outcomes. This pilot study evaluated the use of tamoxifen and endoxifen therapeutic drug monitoring (TDM) using liquid chromatography-tandem mass spectrometry in South African women.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The authors enrolled 20 women with estrogen receptor\u2013positive breast cancer who were treated with tamoxifen; performed TDM on them, and assessed their adherence using objective and subjective methods. Objective nonadherence was defined as tamoxifen plasma concentration &lt;60.0 ng\/mL and subjective nonadherence was defined as self-reporting at least 1 missed dose. A Shimadzu LCMS-8040 instrument with an Agilent Poroshell 120 EC-C18 column was used to quantify tamoxifen and endoxifen plasma concentrations using protein precipitation extraction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      The participants' mean age was 45 \u00b1 9.92 years; most had stage 4 breast cancer and were prescribed tamoxifen for palliative treatment. Tamoxifen and endoxifen concentrations were 11.7\u2013340 ng\/mL (median of 136 ng\/mL) and 3.64\u201334.2 ng\/mL (median of 12.4 ng\/mL), respectively. Objective nonadherence was low (5%), whereas subjective nonadherence was high (45%), with weak agreement (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.322). Based on a therapeutic threshold of 5.97 ng\/mL, 20% (95% CI: 8.1%\u201341.6%) had subtherapeutic endoxifen concentrations.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>A liquid chromatography-tandem mass spectrometry method was developed and fully validated according to the ICH M10 guidelines to simultaneously provide objective adherence measurements and TDM in a pilot study. This method enables clinicians to verify medication compliance and determine therapeutic concentrations by quantifying both tamoxifen adherence and endoxifen concentration in a single analysis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/ftd.0000000000001533","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:00:24Z","timestamp":1792159224000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Measurement of Tamoxifen and Endoxifen Concentrations via Liquid Chromatography-Tandem Mass Spectrometry to Assess Adherence and Optimal Concentrations in South Africans with Breast Cancer Participating in a Pilot Trial: A Short Communication"],"prefix":"10.1097","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2097-799X","authenticated-orcid":false,"given":"Justine T.","family":"Govender","sequence":"first","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny M.","family":"Edge","sequence":"additional","affiliation":[{"name":"Division of Surgery, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tselane T.","family":"Thebe","sequence":"additional","affiliation":[{"name":"Division of Radiation Oncology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy A.","family":"Kellermann","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric H.","family":"Decloedt","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Faculty of Medicine and Health Sciences, Stellenbosch University, Stellenbosch, South Africa;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"R1-20261016","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcancer.2021.07.010","article-title":"Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies","volume":"82","author":"Zhao","year":"2022","journal-title":"Semin Cancer Biol."},{"key":"R2-20261016","doi-asserted-by":"crossref","first-page":"101645","DOI":"10.1016\/j.jocs.2022.101645","article-title":"A new survival analysis model in adjuvant tamoxifen-treated breast cancer patients using manifold-based semi-supervised learning","volume":"61","author":"Yansari","year":"2022","journal-title":"J Comput Sci."},{"key":"R3-20261016","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s10549-022-06835-6","article-title":"The impact of HIV on non-adherence for tamoxifen among women with breast cancer in South Africa","volume":"197","author":"Ayeni","year":"2023","journal-title":"Breast Cancer Res Treat."},{"key":"R4-20261016","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin."},{"key":"R5-20261016","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.vhri.2021.05.005","article-title":"The cost-effectiveness of adjuvant tamoxifen treatment of hormone receptor-positive early breast cancer among premenopausal and perimenopausal Ghanaian women","volume":"25","author":"Addo","year":"2021","journal-title":"Value Health Reg Issues."},{"key":"R6-20261016","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.bpobgyn.2022.03.018","article-title":"Breast cancer screening in low and middle-income countries","volume":"83","author":"Newman","year":"2022","journal-title":"Best Pract Res Clin Obstet Gynaecol."},{"key":"R7-20261016","doi-asserted-by":"crossref","first-page":"231","DOI":"10.4331\/wjbc.v6.i3.231","article-title":"Current medical treatment of estrogen receptor-positive breast cancer","volume":"6","author":"Lumachi","year":"2015","journal-title":"World J Biol Chem."},{"key":"R8-20261016","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.cpet.2018.02.006","article-title":"Overview of breast cancer therapy","volume":"13","author":"Moo","year":"2018","journal-title":"PET Clin."},{"key":"R9-20261016","doi-asserted-by":"crossref","first-page":"e2244849","DOI":"10.1001\/jamanetworkopen.2022.44849","article-title":"Association of adherence to endocrine therapy among patients with breast cancer and potential drug-drug interactions","volume":"5","author":"Rassy","year":"2022","journal-title":"JAMA Netw Open."},{"key":"R10-20261016","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/tpj.2014.34","article-title":"Tamoxifen metabolism predicts drug concentrations and outcome in premenopausal patients with early breast cancer","volume":"15","author":"Saladores","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"R11-20261016","doi-asserted-by":"crossref","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-15-1470","article-title":"Dose escalation of tamoxifen in patients with low endoxifen level: evidence for therapeutic drug monitoring\u2014the TADE study","volume":"22","author":"Fox","year":"2016","journal-title":"Clin Cancer Res."},{"key":"R12-20261016","doi-asserted-by":"crossref","first-page":"1564642","DOI":"10.3389\/or.2025.1564642","article-title":"Treating ER-positive breast cancer: a review of the current FDA-approved SERMs and SERDs and their mechanisms of action","volume":"19","author":"Kim","year":"2025","journal-title":"Oncol Rev."},{"key":"R13-20261016","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1097\/FTD.0000000000000195","article-title":"The effect of tamoxifen dose increment in patients with impaired CYP2D6 activity","volume":"37","author":"Welzen","year":"2015","journal-title":"Ther Drug Monit."},{"key":"R14-20261016","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s40262-021-01077-z","article-title":"Therapeutic drug monitoring of endoxifen for tamoxifen precision dosing: feasible in patients with hormone-sensitive breast cancer","volume":"61","author":"Braal","year":"2022","journal-title":"Clin Pharmacokinet."},{"key":"R15-20261016","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3390\/jpm13020272","article-title":"Pharmacokinetics of tamoxifen and its major metabolites and the effect of the African ancestry specific CYP2D6*17 variant on the formation of the active metabolite, endoxifen","volume":"13","author":"Kanji","year":"2023","journal-title":"J Pers Med."},{"key":"R16-20261016","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/cancers11091353","article-title":"CYP2D6 genotype predicts plasma concentrations of tamoxifen metabolites in Ethiopian breast cancer patients","volume":"11","author":"Ahmed","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R17-20261016","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ebiom.2017.02.017","article-title":"African genetic diversity: implications for cytochrome P450-mediated drug metabolism and drug development","volume":"17","author":"Rajman","year":"2017","journal-title":"EBiomedicine"},{"key":"R18-20261016","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","article-title":"Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes","volume":"89","author":"Madlensky","year":"2011","journal-title":"Clin Pharmacol Ther."},{"key":"R19-20261016","doi-asserted-by":"crossref","first-page":"370","DOI":"10.22159\/ijap.2018.v10s1.82","article-title":"Simultaneous quantification of tamoxifen and 4-hydroxy-N-desmethyltamoxifen levels in human plasma by liquid chromatography-tandem mass spectrometry: development and application in breast cancer patients","volume":"10","author":"Harahap","year":"2018","journal-title":"Int J Appl Pharmaceutics."},{"key":"R20-20261016","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1200\/JCO.19.01758","article-title":"Serum detection of nonadherence to adjuvant tamoxifen and breast cancer recurrence risk","volume":"38","author":"Pistilli","year":"2020","journal-title":"J Clin Oncol."},{"key":"R21-20261016","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1159\/000512840","article-title":"Adherence to newly implemented tamoxifen therapy for breast cancer patients in rural Western Ethiopia","volume":"16","author":"Reibold","year":"2021","journal-title":"Breast Care (Basel)"},{"key":"R22-20261016","doi-asserted-by":"crossref","first-page":"283","DOI":"10.3389\/fphar.2020.00283","article-title":"Integrated data analysis of six clinical studies points toward model-informed precision dosing of tamoxifen","volume":"11","author":"Klopp-Schulze","year":"2020","journal-title":"Front Pharmacol."},{"key":"R24-20261016","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.talanta.2014.10.040","article-title":"Ultra-high performance liquid chromatography tandem mass spectrometric method for the determination of tamoxifen, N-desmethyltamoxifen, 4-hydroxytamoxifen and endoxifen in dried blood spots\u2014development, validation and clinical application during breast cancer adjuvant therapy","volume":"132","author":"Antunes","year":"2015","journal-title":"Talanta"},{"key":"R25-20261016","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s10549-013-2826-1","article-title":"Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care","volume":"143","author":"Jager","year":"2014","journal-title":"Breast Cancer Res Treat."},{"key":"R26-20261016","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1310\/ENXW-95PB-5NGW-1F40","article-title":"Measuring adherence to antiretroviral medications in clinical trials","volume":"1","author":"Miller","year":"2000","journal-title":"HIV Clin Trials."},{"key":"R27-20261016","first-page":"51","article-title":"Factors influencing pharmacokinetics of tamoxifen in breast cancer patients: a systematic review of population pharmacokinetic models","volume":"12","author":"Dilli Batcha","year":"2022","journal-title":"Biology (Basel)"},{"key":"R28-20261016","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.3390\/pharmaceutics14122731","article-title":"Model-informed precision dosing (MIPD)","volume":"14","author":"P\u00e9rez-Blanco","year":"2022","journal-title":"Pharmaceutics"},{"key":"R29-20261016","first-page":"711","article-title":"About the benefits and limitations of pilot studies","volume":"81","author":"Dworschak","year":"2015","journal-title":"Minerva Anestesiol."}],"container-title":["Therapeutic Drug Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001533","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T14:00:27Z","timestamp":1792159227000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/FTD.0000000000001533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":28,"URL":"https:\/\/doi.org\/10.1097\/ftd.0000000000001533","relation":{},"ISSN":["0163-4356","1536-3694"],"issn-type":[{"value":"0163-4356","type":"print"},{"value":"1536-3694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"2026-05-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}